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Abstract
Background: The p53 tumor suppressor and its related protein, p73, share a homologous DNA
binding domain, and mouse genetics studies have suggested that they have overlapping as well as
distinct biological functions. Both p53 and p73 are activated by genotoxic stress to regulate an array
of cellular responses. Previous studies have suggested that p53 and p73 independently activate the
cellular apoptotic program in response to cytotoxic drugs. The goal of this study was to compare
the promoter-binding activity of p53 and p73 at steady state and after genotoxic stress induced by
hydroxyurea.
Results: We employed chromatin immunoprecipitation, the NimbleGen promoter arrays and a
model-based algorithm for promoter arrays to identify promoter sequences enriched in anti-p53
or anti-p73 immunoprecipitates, either before or after treatment with hydroxyurea, which
increased the expression of both p53 and p73 in the human colon cancer cell line HCT116-3(6).
We calculated a model-based algorithm for promoter array score for each promoter and found a
significant correlation between the promoter occupancy profiles of p53 and p73. We also found
that after hydroxyurea treatment, the p53-bound promoters were still bound by p73, but p73
became associated with additional promoters that that did not bind p53. In particular, we showed
that hydroxyurea induces the binding of p73 but not p53 to the promoter of MLH3, which encodes
a mismatch repair protein, and causes an up-regulation of the MLH3 mRNA.
Conclusion: These results suggest that hydroxyurea exerts differential effects on the promoter-
binding functions of p53 and p73 and illustrate the power of model-based algorithm for promoter
array in the analyses of promoter occupancy profiles of highly homologous transcription factors.
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Background
The p53-family of transcription factors, p53, p63, and
p73, regulate genes involved in DNA repair, cell cycle
checkpoints, and apoptosis in response to cellular stress
[1]. Mouse genetics studies have suggested that these tran-
scription factors have common and unique biological
functions. In contrast to p53-deficient mice, which are
predisposed to early cancer development [2], mice with
loss of p63 or p73 have profound defects in their epithe-
lial and neuronal development, respectively [3,4]. Com-
pound heterozygous p63+/-p53+/-  or p73+/-p53+/-  mice
were found to have higher incidence of tumorigenesis and
increased metastatic ability than p53+/-  single hetero-
zygous mice, suggesting a collaborative role for the p53-
family in tumor suppression [5]. In addition, the com-
bined loss of p73 and p53 induces genomic instability
more severely than that induced by loss of p53 alone [6].
Taken together, these observations suggest that p53, p63,
and p73 have redundant as well as non-overlapping func-
tions.
With the advent of the chromatin immunoprecipitation
on DNA chip (ChIP-chip), which allows for a genome-
wide analysis of transcription factor-binding sites in cells,
a number of studies have been conducted to identify
genomic-binding sites of the p53-family members [7-14].
These studies have each analyzed the binding sites of an
individual member of the p53-family, notably p53 itself.
In one study, a comparison of the genomic-binding sites
between p53 and p73 was carried out under conditions of
over-expression [14]. In this study, we used the Nimble-
Gen 1.5-kb promoter array platform covering 24,135
human promoters to examine the promoter occupancy
profiles of endogenous p53 and p73 in the human colon
cancer line HCT116-3(6), both before and after hydroxy-
urea (HU) treatment. We developed a model-based anal-
ysis of the hybridization results and identified a series of
p53 and p73 associated promoters. This study has
revealed a previously unknown effect of HU on the pro-
moter occupancy profiles of two highly related transcrip-
tion factors.
Results
Establishing the experimental system
The colon cancer cell line HCT116-3(6) expresses p53 and
p73 at a much higher level than p63, shown by immuno-
blotting (Figure 1a, left panel) and quantitation of mRNA
(see Figure S1A in Additional file 1); furthermore, treat-
ment with HU increased the steady-state levels of p53 and
p73, but not p63 (Figure 1a, left panel). The p63 protein
was detectable in MCF7 cells, but HU did not increase its
level in this breast cancer cell line (Figure 1a, right panel).
Time-course experiments showed that p53 levels
increased steadily between 12 hours and 48 hours after
HU addition, while p73 levels reached a peak at 24 hours
of HU addition (see Figure S1B in Additional file 1). We
therefore performed subsequent experiments with a 16-
hour treatment of HU, a time at which both p53 and p73
levels were higher than the basal levels.
We prepared affinity-purified anti-p73 polyclonal anti-
body and demonstrated that the anti-p73 (827) antibody
reacted with four isoforms of p73 (a, b, g and d) but not
p53 (see Figure S1C in Additional file 1). We performed
chromatin immunoprecipitations (ChIPs) with anti-p53
and our home-made anti-p73 (827) antibodies followed
by Western blotting and observed higher levels of p53 and
p73 in cross-linked chromatin preparations from HU-
treated cells (Figure 1b), consistent with increased levels
of both proteins (Figure 1a). Therefore, the antibodies can
react with p53 or p73 and HU treatment did not appear to
mask the p53 and p73 epitopes in the context of cross-
linked chromatin.
We established the specificity of anti-p53 and anti-p73
ChIP, taking advantage of the fact that p53 and p73 both
bind to the distal p53 response element located about 2.3
kb upstream of the transcription start site in the p21cip1
promoter [15,16] (Figure 1c). To test the specificity of our
anti-p73 (827) antibody, we performed ChIP in p73-/- 3T3
cells reconstituted with either the empty murine stem cell
virus (MSCV) vector or human p73-a. We found that our
anti-p73 antibody specifically brought down the p21cip1
promoter-distal region in p73-/- 3T3 cells reconstituted
with human p73-a but not with MSCV (Figure 1d, top
panel). Similarly, we performed ChIP with anti-p53 in the
p53-deficient human Saos2 cells and detected no enrich-
ment of the p21cip1 promoter-distal region (Figure 1d,
bottom panel). Next, we used cross-linked chromatin
from untreated and HU-treated HCT116-3(6) cells to per-
form ChIPs with antibodies against p53 or p73 and meas-
ured the enrichment of the p21cip1 promoter sequence in
the immunoprecipitates by quantitative polymerase chain
reaction (qChIP). We found that both p53 and p73 occu-
pied the distal binding site in the p21cip1 promoter (Fig-
ure 1e). Moreover, p21cip1 promoter occupancy by p53
and p73 was increased following HU treatment (Figure 1e
and 1f). Taken together, these results showed that the
HCT116-3(6) cells and the ChIP conditions we estab-
lished can be used to study the promoter occupancy pro-
files of p53 and p73.
ChIP-chip experiments using promoter arrays
Previous studies have shown that the majority of p53
genomic-binding sites fall outside of the promoter region
[7,13]. In this study, we used the 1.5-kb NimbleGen pro-
moter arrays, which contain probes corresponding to the
-1.3-kb to +200-bp region relative to the transcription
start site of 24,135 human genes, and thus limiting the
comparison only to the promoter occupancy profiles ofBMC Biology 2009, 7:35 http://www.biomedcentral.com/1741-7007/7/35
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Hydroxyurea-induced accumulation of p53 and p73 and increased occupancy of the p21cip1 promoter in HCT116-3(6) cells Figure 1
Hydroxyurea-induced accumulation of p53 and p73 and increased occupancy of the p21cip1 promoter in 
HCT116-3(6) cells. (a) The indicated cells were treated with or without HU (1 mM) for 16 hours, and the indicated proteins 
were detected by immunoblotting as described in Methods. (b) Higher levels of p53 and p73 induced by HU correlates with 
increased association with chromatin. HCT116-3(6) cells with or without HU treatment were subjected to chromatin immu-
noprecipitation (ChIP) using the indicated antibodies followed by immunoblotting with the indicated antibodies. (c) Polymerase 
chain reaction (PCR) primer designed for the distal p53 binding site in the p21cip1 promoter. (d) ChIP specificity. p73 -/- 3T3 
cells reconstituted with either the empty vector or human p73a were treated with or without HU as in (a) and were subjected 
to ChIP using the indicated antibodies. Enrichment of the p21cip1 promoters was assessed by PCR using primers encompassing 
the p53-binding site in the distal region of the p21cip1 promoter as shown in (c). (e) Increased occupancy of the p21cip1 pro-
moter by p53 and p73 following HU treatment. Chromatin from HCT116-3(6) cells with or without HU treatment were 
immunoprecipitated with the indicated antibodies (lanes 2, 4, 6, and 8) and followed by PCR analysis using the primers as 
shown in (c). M = mouse immunoglobulin G (IgG); R = rabbit IgG. Fold enrichment relative to the IgG sample was determined 
by quantitative PCR (f) Quantitative real time-PCR analysis of (e) shown as percent total input DNA.BMC Biology 2009, 7:35 http://www.biomedcentral.com/1741-7007/7/35
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Model-based analysis for promoter array Figure 2
Model-based analysis for promoter array. (a) Scheme for chromatin immunoprecipitation (ChIP) on DNA chip analysis. 
(b) Confirmation of ChIP and ligation-mediated -polymerase chain reaction amplified amplicons. ChIPs were performed as 
described in Figure 1(e). Enrichment of the p21cip1 distal promoter region was used to check the specificity of the samples 
prior to hybridization, M = mouse immunoglobulin (IgG); R = rabbit IgG. (c) Outline of the bioinformatics analysis for the iden-
tification of p53 and p73 ChIP-enriched promoters. (d) Definition of window and promoter-scores. a-g: window score; *: pro-
moter-score. (e) Pair-wise scatter plots of the promoter-scores for the input channels (top). R2 values are summarized in the 
table. (f) Pair-wise scatter plots of the promoter-scores between the ChIP and input channels (top). R2 values are summarized 
in the table. (g) Pair-wise scatter plots of the promoter-scores between the ChIP and IgG channels (top). R2 values are summa-
rized in the table. (h) Correlation between the ChIP channels and OCT4 ChIP control. R2 values are summarized in the table.BMC Biology 2009, 7:35 http://www.biomedcentral.com/1741-7007/7/35
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p53 and p73. To generate the hybridization probes, cross-
linked chromatin from untreated or HU-treated HCT116-
3(6) cells were immunoprecipitated with anti-p53 or anti-
p73 and the resulting DNA was amplified by ligation-
mediated PCR (LM-PCR) (Figure 2a). The specificity of
the amplified DNA was confirmed by PCR using primers
specific for the p21cip1 promoter-distal region (Figure
2b). As expected, the p21cip1 promoter-distal region was
enriched in the amplicons derived from the anti-p53 and
anti-p73 ChIP, but not from the immunoglobulin G (IgG)
ChIP (Figure 2b). We then labeled the p53-ChIP or p73-
ChIP amplicons and the total input amplicons with Cy3
and Cy5 dye, respectively, and co-hybridized input and
ChIP DNA probes from the -HU or +HU condition to four
NimbleGen 1.5-kb promoter arrays (Figure 2a).
We developed a model-based algorithm for promoter
arrays (MAP), which is similar to the model-based algo-
rithm for tiling arrays (MAT) [17] to analyze the hybridi-
zation results (Figure 2c and details can be found in
Additional data file 2). The NimbleGen promoter array
platform used in this study contains 15 50-mer probes
tiled across each 1.5-kb promoter-proximal region. We
applied MAP to obtain standardized fluorescence values
for each probe on the array, following adjustments for
probe copy numbers and guanine-cytosine content [17].
We then calculated a series of window scores, which are
the median of the MAP values of three probes within a
series of sliding windows (Figure 2d). The highest window
score is then assigned as the promoter-score (Figure 2d).
A false discovery rate (FDR) is calculated for each pro-
moter-score according to the method developed by Storey
and Tibshirani [18]. Instead of taking the ratios of pro-
moter-scores between the input and ChIP DNA, we com-
pared the promoter-scores and the FDR of the input and
ChIP channels as independent entities (see Additional file
3).
We first compared the promoter-scores deduced from
hybridization with the total input DNA (Figure 2e), and
found the R2 value of 0.9363 (-HU) and 0.9122 (+HU)
between two independent hybridizations, demonstrating
a high degree of technical reproducibility (Figure 2e). The
R2 values between input DNA from -HU versus +HU cells
were in the range 0.6196 to 0.6344, representing the
experimental correlation generated from two different
biological samples (Figure 2e). Comparison of input ver-
sus ChIP signals on each of the four arrays showed R2 val-
ues in the range 0.2130 to 0.3047 (Figure 2f). We then
calculated the MAP scores from an IgG-ChIP DNA hybrid-
ization result from Xu et al. [19], and found similarly low
R2 values in the range 0.1891 to 0.2660 when compared
with the p53- or p73-ChIP DNA (Figure 2g). In addition,
we calculated the MAP scores from an Oct4-ChIP DNA
result from Jin et al. [20] and found R2 values again to be
in the range 0.1991 to 0.2760 when compared with the
p53- or p73-ChIP DNA (Figure 2h). It should be noted
that the MAP scores deduced for input DNA from differ-
ent laboratories correlated with one another at R2 values
of 0.5, which was in the range (i.e. 0.6) of the two input
DNA comparisons from this study. These results demon-
strate the feasibility of using MAP to compare the different
hybridization datasets obtained from the same array plat-
form. When the comparisons were made between p53-
and p73-ChIP DNA, we found that the R2 values were in
the range 0.4846 to 0.7121 (Figure 2h), which were in the
range of comparing input DNA hybridization results (bio-
logical repeats) from different laboratories. Taken
together, these results indicated that p53- and p73-ChIP
DNA shared a high degree of similarity, which was signif-
icantly different from the total input DNA and the IgG-
and Oct4-ChIP DNA.
Validation of the MAP window and promoter-scores
To determine experimentally the confidence level of the
MAP-calculated scores, we performed qChIP on a series of
promoters selected across MAP-deduced FDR values from
0 to 0.05 (see Figure S2 in Additional file 1). We calcu-
lated occupancy units (OU) from each qChIP experiment
as previously described in Yang et al. [8]. We found that
the log2 OU for the negative controls fell significantly
below 1 (P < 0.005), thus, we assigned log2 OU of >1 as a
positive qChIP result, indicative of p53 or p73 binding to
a promoter region. We scanned the 1.5-kb region of an X-
chromosome promoter identified by MAP to bind p53
and p73 by qChIP, and found that the log2 OU correlated
well with the MAP-deduced window scores (see Figure
S2a in Additional file 1). We then performed qChIP on 20
selected promoters using primers flanking each of the 250
bp windows with the peak MAP scores (see Figure S2b in
Additional file 1). We chose these 20 promoters for qChIP
verification experiments because they showed no signifi-
cant enrichment in the input DNA samples (FDR > 0.8),
but in the four ChIP DNA samples (p53+/-HU, p73+/-
HU, FDR < 0.05). The results of qChIP OU values of these
20 promoters from each of the four experimental condi-
tions (p53-ChIP +/- HU, p73-ChIP +/- HU) are summa-
rized in Figure S2c in Additional file 1. We also performed
qChIP with IgG, and confirmed that there was no signifi-
cant enrichment of these 20 promoters in the IgG controls
(data not shown).
Based on the qChIP results of the 20 selected promoters,
we determined the false discovery rate (FDRqChIP) using a
weighted approach [8]. We separated the FDRMAP values
into three bins (0 to 0.005, 0.005 to 0.01, 0.01 to 0.05)
(see Figure S2d in Additional file 1) and assigned FDRq-
ChIP to each bin (see Figure S2d in Additional file 1). At
FDRMAP < 0.005, the FDRqChIP was 17% for p53 (-HU),
suggesting a confidence level of 83%. Similarly, at FDRMAPBMC Biology 2009, 7:35 http://www.biomedcentral.com/1741-7007/7/35
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< 0.005, the FDRqChIP was 21% for p73 (+HU), with a con-
fidence level of 80% (see Figure S2d in Additional file 1).
We then counted the number of promoters showing FDR-
MAP < 0.005 from each of the four ChIP hybridizations and
FDRMAP > 0.8 in the corresponding input hybridization
(for a complete list of these promoters, refer to Additional
file 4). The number of promoters identified this way are:
201 for p53(-HU), 216 for p53(+HU), 360 for p73(-HU),
and 526 for p73 (+HU) (see Figure S2d in Additional file
1).
Comparison of p53 and p73 promoter occupancy profiles
We used linear regression to compare the promoter-scores
from different experiments, because it introduces the least
manipulation (Figure 3). As discussed above, the R2 value
was 0.5964 when the total promoter-scores from the p53-
ChIP (-HU) and the p73-ChIP (-HU) experiments were
compared (Figure 2h). We noted that the R2 values were
consistently lower when comparisons were made between
p73-ChIP (+HU) and any of the other three ChIP DNA
samples (Figure 2h). After the selection of promoters of
confidence levels between 60% and 80% (see Figure S2d
in Additional file 1), we compared their MAP-deduced
promoter-scores across the four ChIP hybridizations: p53
(-HU), p53 (+HU), p73 (-HU), and p73 (+HU) (Figure 3).
As would be expected, the overall correlation was reduced
when the p73 (+HU) subset of promoter-scores was com-
pared. We found R2 values ranging from 0.09 to 0.28
when the promoter sets were selected from the p53 (-HU),
p53 (+HU), and p73 (-HU) hybridization experiments
(Figure 3a). However, the R2 values were in the range
0.006 to 0.01 with the promoter set selected from the p73
(+HU) hybridization experiment (Figure 3a). The over-
laps among the four subsets of promoters are also
depicted as Venn diagrams (Figure 3b). Taken together,
the correlation analysis suggested that while p53 and p73
bound to similar promoters at steady state and after HU-
treatment, p73 appeared to bind to additional promoters
in HU-treated cells.
Next, we selected additional binding sites for qChIP veri-
fication to identify HU-induced and p73-specific binding
sites by the following criteria: those with FDRMAP < 0.005
in the p73-ChIP +HU hybridization experiment and FDR-
MAP > 0.8 in the other three ChIP hybridization experi-
ments, and FDRMAP > 0.8 in all four input hybridizations.
In addition, we selected other promoters with FDRMAP <
0.005 in at least one of the four ChIP hybridization exper-
iments and FDRMAP > 0.8 in all four input hybridizations
(Figure 4). All together, 12 promoters with different bind-
ing patterns were tested by qChIP. We verified that p53
and p73 indeed occupied common and distinct promot-
ers identified by MAP. Out of the 12 promoters tested,
three were constitutively bound by p53 and p73 in cells
untreated or treated with HU (Figure 4). With the other
nine promoters, we found HU-regulated binding in sev-
eral combinations (Figure 4). These qChIP results demon-
strate that the MAP-generated data from this study are
useful in identifying p53 and/or p73-associated promot-
ers in untreated and HU-treated cells.
Correlation between promoter occupancy and regulation 
of gene expression
To examine the relationship between promoter occu-
pancy and gene expression, we depleted p53 and p73 via
small interfering RNA (siRNA) in HCT116-3(6) cells and
then performed microarray analysis of 32,000 genes
before or after HU treatment using the Phalanx expression
array platform (Figure 5a and 5b). Genes that are com-
mon between the NimbleGen and Phalanx arrays were
then analyzed (Figure 5c). We found that between 6% and
14% of p53 and p73 bound promoters at FDRMAP < 0.05
exhibited significant changes in mRNA expression when
p53 and p73 were simultaneously knocked down by
siRNA (Figure 5c). Among them, we identified 18 p53-
bound promoters that showed a significant change in
gene expression when p53 and p73 were knocked down
in the -HU condition (Figure 5c and Additional file 5).
Among these 18 promoters, we found that the expression
of metalloproteinase 12 (MMP12) was up-regulated upon
depletion of p53 and p73, consistent with a previous
report that p53 is a negative regulator of MMP9 [21] (see
Additional file 5). We also identified 20 p73-bound pro-
moters that showed a significant change in gene expres-
sion when p53 and p73 were simultaneously knocked
down under the -HU condition (see Additional file 5).
Moreover, we identified 25 p53-bound promoters that
showed a significant change in gene expression when p53
and p73 were simultaneously knocked down in the +HU
condition (see Additional file 5). Under the same condi-
tion, we identified 63 p73-bound promoters whose
expression was significantly affected by the double knock-
down of p53 and p73 (see Additional file 5). Taken
together, while the correlation between binding and regu-
lation of expression is limited [8,22-24], the combination
of ChIP-chip and gene expression profiling with siRNA is
feasible in the identification of p53/p73-regulated pro-
moters.
MLH3 as a p73-specific target in HU-treated cells
As the correlation analysis suggested that unique pro-
moter sequences were enriched in the p73-ChIP (+HU)
experiment, we further examined some of these promot-
ers that are bound by p73 but not p53 in HU-treated cells.
By comparing the four selected promoter sets (see Figure
S2d in Additional file 1 and Figure 3), the MAP analysis
suggested that p73 was selectively bound to 351 promot-
ers in HU-treated cells (see in Additional file 6). Among
them, we tested two promoters by qChIP: MLH3, a DNA
mismatch repair gene involved in microsatellite instabil-BMC Biology 2009, 7:35 http://www.biomedcentral.com/1741-7007/7/35
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Comparison of p53 and p73 promoter occupancy profiles Figure 3
Comparison of p53 and p73 promoter occupancy profiles. (a) Summary of the correlation analysis on selected pro-
moters using model-based algorithm for promoter arrays promoter-scores (column 3), or NimbleGen log2 ratios (column 4). 
R2 values represent the degree of correlation and P values represent the significance of correlation. (b) Venn diagrams depict-
ing the number of common and distinct promoters occupied by p53 and/or p73 using FDRMAP < 0.005.BMC Biology 2009, 7:35 http://www.biomedcentral.com/1741-7007/7/35
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ity as well as meiotic arrest [25,26], and ETF1, eukaryotic
translation termination factor gene 1, involved in the ter-
mination translation [27]. We performed RT-PCR experi-
ments and measured the mRNA levels in HCT116-3(6)
cells stably expressing p53 or p73 small hairpin RNA
(shRNA) (Figure 6a). As a positive control, we showed
that the knockdown of p53 or p73 each reduced the
steady-state levels of p21Cip1 in untreated cells albeit to
different extents (Figure 6b). We found that the ETF1 pro-
moter sequence was enriched in the anti-p73 but not the
anti-p53 ChIP (Figure 6c). The qChIP experiment showed
that p73 binding was detected in untreated and HU-
treated cells (Figure 6c). The peak MAP window in the
ETF1 promoter contains a p53-consensus binding
sequence (Figure 6d), although our current data are not
sufficient to support the conclusion that p73 specifically
bound to that consensus sequence. HU treatment did not
alter the mRNA levels of ETF1, and the knockdown of p53
or p73 also did not affect its expression in response to HU
(Figure 6e). Therefore, the association of p73 with ETF1
appeared to be inconsequential to its expression in
HCT116-3(6) cells. By contrast, the qChIP results showed
that p73 associated with the MLH3 promoter only in HU-
treated cells, and that p53 did not bind to this promoter
in either untreated or HU-treated cells (Figure 6f). Again,
we detected a p53-consensus sequence in the window cor-
responding to the peak MAP score (Figure 6g). Further-
more, we detected a low but statistically significant
induction of MLH3 mRNA in HU-treated cells, with either
the LacZ or the p53 shRNA (Figure 6h). Interestingly, the
knockdown of p73 abolished the HU-induced up-regula-
tion of MLH3 (Figure 6h), indicating that the binding of
p73 to this promoter correlated with an up-regulation of
its expression.
Discussion
In this study, we established an experimental system to
examine the in vivo promoter occupancy profiles of p53
Summary of quantitative chromatin immunoprecipitation analysis of selected promoters for p53 and p73 binding before and  after hydroxyurea treatment Figure 4
Summary of quantitative chromatin immunoprecipitation analysis of selected promoters for p53 and p73 
binding before and after hydroxyurea treatment. Cross-linked chromatin from untreated hydroxyurea (-HU) or 
hydroxyurea-treated (+HU) (1 mM, 16 hours) HCT116-3(6) cells were immunoprecipitated with the indicated antibodies and 
followed by polymerase chain reaction analysis using the primers flanking the sequences corresponding to the model-based 
algorithm for promoter array promoter-score window in each of the promoters. Data shown are log2 occupancy units from 
two independent chromatin immunoprecipitation experiments +/- standard deviation. log2 occupancy units >1: significant 
enrichment of the selected promoter sequences in the anti-p53 or anti-p73 chromatin immunoprecipitation.
Promoter      log2 OU
IgG p53 (+HU) IgG IgG p73 (+HU) IgG
   
    GPR8 <0 7.01±0.93 <0 <0 4.11±0.38 <0
n/a <0 <0 <0 6.36±0.41 <0
<0 <0 <0 6.48±0.23 <0
LYL1 3.30±1.03 <0 <0 4.36±0.07 <0 <0
SEMA4D Semaphorin   <0 <0 <0 <0 <0 <0
HSAP0406S00034475 NM_058186 FAM3B
Family with 
sequence similarity 4.9±0.27 <0 <0 <0 4.17±0.24 <0 1.18±0.31 <0
HSAP0406S00023356 AK127211
cDNA 
FLJ45278
n/a 6.9±0.74 <0 <0 <0 2.67±1.47 <0 1.20±0.66 <0
HSAP0406S00025741 AB032525 NKCC2
Na-K-2Cl co- 
transporter 3.18±0.96 <0 <0 <0 <0 <0 3.75±0.1 <0
HSAP0406S00022455 AK094261
cDNA
FLJ36942 4.65±0.65 <0 <0 <0 <0 <0 <0
HSAP0406S00019480 NM_053017 ART5
ADP-
ribosyltransferase  <0 <0 2.1±0.3 <0 3.89±0.24 <0 1.7±0.38 <0
MYL7 <0 <0 <0 3.44±0.28 <0 <0
HSAP0406S0006063 NM_024080 TRPM8
  potential cation 
channel <0 <0 <0 <0 4.95±0.91 <0 <0 <0
<0 HSAP0406S00013662 NM_021223 Myosin light chain   6.34±3.74
HSAP0406S00016860 NM_006378 5.7±2.77 2.45±1.41
0.37±0.76 HSAP0406S00031561 NM_005583
lymphoblastic 
leukemia derived 
sequence  
   HSAP0406S00027218 AJ223280 8.02±0.45 9.35±1.02    pp36 phosphoprotein
   HSAP0406S00034186 AK127768
  cDNA 
FLJ45869 6.51±0.94
Gene Name
   HSAP0406S00034239 NM_005286
G-protein coupled 
receptor
NimbleGen Probe ID Gene ID Protein p53 (-HU) p73 (-HU)
5.00±1.01 6.03±0.09
4.82±3.67
8.96±1.02 3.94±0.54
1.16±1.02
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and p73 before and after HU treatment (Figure 1 and Fig-
ure S1 in Additional file 1). Using a model-based analysis
(MAP) of array hybridization signals, we identified p53-
and p73-ChIP-enriched promoters and determined the
qChIP FDRs (Figure 2 and Figure S2 in Additional file 1).
Comparisons of promoter sets selected with FDRMAP of <
0.005 showed that HU induces the binding of p73 to
unique promoters not shared by p53 (Additional files 4
and 6). Gene ontology (GO)-based analyses showed that
these HU-induced p73-binding promoters belong to dis-
tinct GO terms (Additional file 7). Among them, we have
confirmed the MLH3 promoter as a HU-induced and p73-
specific target (Figure 6). Our study has gone beyond the
simple cataloging of p53 and p73 binding sites and dem-
onstrated the power of MAP in elucidating the promoter-
binding functions of p53 and p73 before and after the
exposure of cells to genotoxic stress.
MAP analysis of ChIP-chip results
Rank-based target identification [28] or single-array
model [29] are the two main statistical approaches that
have been employed to analyze ChIP-chip data. In both
methods, the enrichment is defined as the ratio of the
ChIP DNA signal over the input DNA signal on the array.
In the rank-based target identification method, genomic
loci are ranked according to their fluorescence ratios and
Integration of chromatin immunoprecipitation on DNA chip and gene expression profiling Figure 5
Integration of chromatin immunoprecipitation on DNA chip and gene expression profiling. (a) Small interfering 
RNA (siRNA)-mediated knockdown of p53 and/or p73 in HCT16-3(6) cells. Immunoblot of lysates from untreated or hydrox-
yurea-treated HCT116-3(6) cells (1 mM, 16 hours) following transfection with chemically synthesized siRNA oligos against 
lacZ, p53, and/or p73. (b) Flow chart for the integrated analysis of chromatin immunoprecipitation on DNA chip with expres-
sion profiling. (c) Summary of the relationship between p53/p73 binding and gene expression. Column 4: expression in p53 and 
p73 siRNA-transfected cells is lower than that of lacZ-transfected cells. Column 5: expression in p53 and p73 siRNA-trans-
fected cells is higher than that of lacZ-transfected cells.BMC Biology 2009, 7:35 http://www.biomedcentral.com/1741-7007/7/35
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MLH3 is a p73-specific target induced by hydroxyurea Figure 6
MLH3 is a p73-specific target induced by hydroxyurea. (a) Western blotting analysis of lysates from untreated or 
hydroxyurea (HU)-treated HCT116-3(6) cells (1 mM, 16 hours) stably expressing lacZ, p53, or p73 small hairpin RNA 
(shRNA). (b) Effect of p53 or p73 knockdown on p21cip1 gene expression. Real-time RT-PCR analysis of the steady-state 
p21cip1 mRNA level in HCT116-3(6) cells stably expressing p53 or p73 shRNA *P < 0.05, n = 3 (c) Chromatin from untreated 
or HU-treated HCT116-3(6) cells (1 mM, 16 hours) were immunoprecipitated with the indicated antibodies and followed by 
PCR analysis using the primers flanking the ETF1 promoter region defined by the model-based algorithm for promoter array 
(MAP) promoter-score. Data are represented as log2 occupancy units from two independent ChIP experiments +/- standard 
deviation. Enrichment was confirmed by agarose gel electrophoresis analysis (bottom). (d) MAP window sequence. Primers 
used for qChIP analysis in (c) are indicated in bold. The core consensus sequence of p53 is underlined. (e) ETF1 mRNA level in 
the stable cell lines described in (a) with or without HU treatment was examined by RT-PCR analysis. (f) qChIP analysis of the 
MLH3 promoter was performed as in (c). (g) MAP window sequence. Primers used for qChIP analysis in (f) are shown in bold. 
The core consensus sequence of p53 is underlined. The p53 half site is highlighted in red and underline indicates mismatches. 
(h) Effect of p53 or p73 knockdown on MLH3 gene expression. Same analysis was carried out as in (e). *P < 0.05, n = 3.
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a median percentile rank for calling a positive target is
determined across independent micro-array hybridiza-
tions. The single-array error method assumes that the log2
ratios in a ChIP-chip experiment follow a normal distribu-
tion and determines the significance of the enrichment by
calculating a one-sided probability. Targets are usually
selected by a P value cutoff. Application of these analytic
methods requires multiple replicates that are prohibi-
tively expensive with the ChIP-chip experiments.
Johnson et al. [17] developed MAT, which utilizes data
from a single chip for standardization without the
requirement of multiple replicates by modeling the base-
line probe behavior based on probe sequence characteris-
tics and probe copy number in the genome. Adopting the
principles of MAT [17], we demonstrated the power of a
model-based algorithm for ChIP-chip data analysis on
promoter arrays (termed MAP). Our study demonstrates
that it is possible to obtain new insights on the promoter
occupancy profiles of transcription factors from single
hybridization experiments at a reduced cost, using infor-
matics tools such as MAP.
Comparison with previous p53 and p73 ChIP-based studies
Of note, the ChIP-chip experiments here did not uncover
a number of previously known, biologically relevant p53
or p73 targets such as p21Cip1 and Mdm2, because the
p53 binding sites in these genes lie outside the 1.5-kb
region covered by the NimbleGen arrays. We thus limited
the comparison to our results and the previous ChIP-
based studies within the 1.5-kb promoter region. A previ-
ous chromatin immunoprecipitation and paired-end
ditag (ChIP-PET) analysis by Wei et al. [7] has identified
541 high-confidence p53 binding sites in 5-flurouracil-
treated HCT116 cells, of which 51 are located within the
promoter-proximal region covered by the NimbleGen
promoter array used in our study and were included in the
MAP analysis. Out of these 51 sites, three and four sites
showed FDRMAP < 0.01 in our p53 (-HU) and p53 (+HU)
experiments, respectively. In addition, two and seven sites
showed significant FDRMAP < 0.01 in our p73 (-HU) and
p73 (+HU) experiments, respectively (see Additional file
8). In another genome-wide ChIP-chip study by Smeenk
et al. [13], 1546 p53 binding sites were identified in actin-
omycin D-treated U2OS cells. Among those, 39 are
located within the region covered by the NimbleGen pro-
moter array used in this study and were included in the
MAP analysis. Of these 39 sites, APG-1 and RNASE7 were
identified to be bound by p53 in untreated and HU-
treated HCT116-3(6) cells, respectively (see Additional
file 8). ACTA2, RNASE7, and AXL were identified to be sig-
nificantly bound by p73 in untreated HCT-116-(3) cells,
with FDRMAP < 0.005. In HU-treated HCT116-3(6) cells,
EPA2R, TRIM22, ACTA2, and RNASE7 were identified to
be significantly bound by p73, with FDRMAP < 0.005 (see
Additional file 8).
We also conducted a comparison between the results from
Wei et al. [7] and Smeenk et al. [13] to evaluate the overlap
between their studies. Only about 10% (4 out of 51) sites
identified from Smeenk et al. [13] overlap with the 54 sites
identified from Wei et al. [7], suggesting a limited overlap
between different studies. Differences in the experimental
conditions (i.e. cells, antibody, drug treatment) and meth-
odologies (ChIP-chip versus ChIP-PET) between the stud-
ies may account for the limited overlaps. Nevertheless, the
various studies have identified promoter targets for p53
and p73. Furthermore, our experimental approach allows
for comparisons of the effect of drugs on the promoter
occupancy profiles of p53 and p73.
Promoter binding specificity of p53 and p73
With a focused analysis of p53 and p73 binding sites
within promoter-proximal regions, we have found that
approximately 50% of the p53-associated promoters con-
tain a p53 consensus site [30], whereas only 20% of the
p73-associated promoters contain such a consensus
sequence (see Additional file 9). It is possible that p73
may bind to an as yet unidentified non-canonical consen-
sus sequence(s). Alternatively, the promoter association
of p73 may be mediated through protein-protein interac-
tions rather than a direct p73-DNA interaction. We have
conducted a motif search against the JASPAR transcription
factor database and found that p53 and p73-bound pro-
moters are statistically enriched with sequence motifs for
the C2H2 zinc finger proteins (i.e. Sp1 and Snail) as well
as the basic helix-loop-helix transcription factors (see Fig-
ure S3b in Additional file 1). In line with this finding, pre-
vious studies have shown that p53 and sp1 can be
physically associated and function cooperatively to regu-
late gene expression of p21Cip1 [31] and Bax [32]. p73
can also interact with sp1 to mediate repression of cyclin
B1 transcription [33]. Together with the motif search, our
results suggested that the differential promoter occupancy
profiles of p53 and p73 in HU-treated cells may be, in
part, due to secondary interactions with other transcrip-
tion factors. Other mechanisms such as post-translational
modification(s) of p53 and p73 and/or histone acetyla-
tion pattern of the target promoters [34] can also account
for the differential effects of HU on the promoter occu-
pancy profiles of p53 and p73.
p53 and p73 promoter occupancy and regulation of gene 
expression
It is typically assumed that transcription factor binding
and gene expression are correlated. However, several stud-
ies have suggested that p53 and p63 binding to the pro-
moters does not directly result in the regulation ofBMC Biology 2009, 7:35 http://www.biomedcentral.com/1741-7007/7/35
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transcription [7,8]. In the case of p53, a ChIP-PET study
by Wei et al. [7] showed that, following 5-fluorouracil
treatment, p53 was bound to 474 promoters but only 122
showed changes in gene expression. Espinosa [35] and
colleagues have proposed that p53 binding is not the rate-
limiting step in promoter regulation, rather it is the post-
binding events such as p53 post-translational modifica-
tions, chromatin modification and/or recruitment of
other transcriptional regulatory proteins that would deter-
mine the activity of p53-bound promoters. Thus, binding
of p53 to the target promoter is not sufficient to result in
transcription regulation. This conclusion is also sup-
ported by a ChIP-chip study of p63, by which only 10%
to 20% of the p63-bound sites identified by ChIP-chip
with FDR < 0.05 showed p63-dependent transcription
regulation [8].
Implications for the phenotypes of the p53 and p73 mouse 
models
Despite a high degree of similarity among the p53-family
members, mouse knockout models suggest that p53 and
p73 have differential biological functions and that they
are not functionally redundant. The constitutional knock-
out of p53 does not cause embryonic or neonatal
lethality. The most significant phenotype of the p53-null
mice is the development of early onset tumors in the testis
and thymus that kill the p53-null mice within the first 6
months of life [2,36]. On the other hand, the constitu-
tional knockout of p73 interferes with embryonic devel-
opment such that the p73-null mice are runt and have
defects in neuronal development and immune function,
as well as abnormalities in pheromone sensory pathways.
The majority of them die of chronic infection by 4 to 6
weeks of age [4]. Recently, Tomasini et al. [37] showed
that TAp73 isoform-specific knockout mice develop a
phenotype intermediate between the phenotypes of p53-/
- and p73-/- mice with respect to infertility and spontane-
ous tumor formation. Moreover, the types of tumor devel-
oped in TAp73-/- mice are different from those displayed
by p53-/- knockout mice. Taken together, differences in the
phenotypes of the p53 and p73 knockout mice suggest
that these two related transcription factors have different
biological functions, particularly during embryonic devel-
opment.
In this study, we examined the promoter-binding profiles
of p53 and p73 at steady state and under conditions of
replication arrest induced by HU. We showed that p53
and p73 are both up-regulated in cells under replication
stress. As anticipated, these two related transcription fac-
tors indeed bind to a common set of promoters at steady
state. Interestingly, however, we found that p73 is
recruited to promoters that are not bound by p53 under
conditions of replication stress. This finding could explain
the different phenotypes of the p53-null and p73-null
mice, that is, the p73 protein is involved in the regulation
of genes that are not controlled by p53 and those gene
functions are required for the proper embryonic develop-
ment of the mouse.
Conclusion
Using ChIP-chip in combination with MAP analysis, we
performed a direct comparison of p53 and p73 promoter
occupancy profiles and our results indicated that p53 and
p73 have overlapping and distinct promoter occupancy
profiles before and after HU treatment. In addition, HU
alters the promoter occupancy profile of p73 more than
that of p53. We also found that HU induces the binding
of p73 to the MLH3 promoter and causing its up-regula-
tion. This study demonstrates the power of bioinformatics
approach to the analyses of promoter occupancy profiles
of highly homologous transcription factors. Our data sug-
gest that p73 regulates a different set of genes than p53 in
response to genotoxic stress, consistent with the mouse
genetic studies showing that these two related transcrip-
tion factors have different biological functions.
Methods
Cell culture and drug treatment
HCT116-3(6) human colorectal cancer cells (ATCC) were
grown in high-glucose (4.5 g/liter) Dulbecco's modified
Eagle medium (CellGro, Mediatech, Manassas, VA, USA)
supplemented with penicillin G (100 U/ml), streptomy-
cin (100 mg/ml), 10% fetal bovine serum (Hyclone,
Logan, Utah, USA). Cells at around 80% confluency were
treated with 1 mM HU (Sigma) for 16 hours.
Immunoblotting
Cells were washed with phosphate buffered saline (PBS)
and lysed in radioimmunoprecipitation buffer (50 mM
Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5% deox-
ycholate, 0.1% SDS, protease inhibitor cocktail) for 15
minutes at 4°C. Lysates were clarified by centrifugation
for 15 minutes at 14,000 rpm and supernatants were col-
lected. Protein concentration in the soluble fraction was
determined by BioRad DC protein assay. The following
antibodies were used at the indicated dilutions to detect
the endogenous proteins: mouse monoclonal anti-p53
(DO1; CalBiochem, San Diego, CA, USA) at 1:1000,
mouse monoclonal anti-p73 (429; Imgenex, San Diego,
CA, USA) at 1:200, and mouse monoclonal anti-p63
(4A4; Pharmingen, San Diego, CA, USA) at 1:300, and
mouse monoclonal anti- a-tubulin (Clone B-5-1-2;
Sigma) at 1:1000 was used as a loading control.
ChIP
HCT116-3(6) cells were cultured in 10-cm plates to 70%
to 80% confluence prior to drug treatment. Cells were
fixed with 1% formaldehyde in serum-free media for 10
minutes at room temperature. Formaldehyde cross-link-BMC Biology 2009, 7:35 http://www.biomedcentral.com/1741-7007/7/35
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ing was quenched with 125 mM glycine (final concentra-
tion). Cells were washed in PBS and nuclei were prepared
as previously described [38]. Cell suspension was soni-
cated 20 seconds for eight times to yield DNA fragments
with average length of about 500 bp using Branson 450
sonifier, setting 4 (25% power output). Lysates were pre-
cleared with Protein A/G sepharose (GE Healthcare Life
Sciences) for 2 hours at 4°C. Approximately 3 × 107 cells
were prepared per immunoprecipitation and incubated
with 5 mg of total monoclonal anti-p53 (1:1 mixtures of
Ab-1 and Ab-12, CalBiochem) or affinity-purified poly-
clonal anit-p73 (827) at 4°C overnight. Equivalent
amounts of normal IgG were used as negative controls.
Protein A/G beads were then added to the immunoprecip-
itate and incubated for 2 hours. Beads were then washed
sequentially once in low salt buffer, once in high salt
buffer, and three times in TE. DNA/protein complexes
were eluted and decross-linked by heating at 65°C over-
night [38,39]. Eluates were treated with Proteinase K and
DNA fragments were extracted with phenol/chloroform
twice and treated with RNase A. DNA fragments were then
purified and eluted in TE using QIAquick PCR purifica-
tion columns (Qiagen).
NimbleGen promoter array analysis
Total input and ChIP DNA prepared from untreated or
HU-treated cells were amplified by LM-PCR as previously
described [40] and hybridized to 1.5-kb promoter arrays
manufactured by NimbleGen Systems Inc. (Madison, WI,
USA). The 1.5-kb promoter array platform is a single-array
design that covers 24,135 human promoters. For each
promoter, 15 50-mer probes were designed to tile across
the proximal region from -1300 to +200 relative to the
transcription start site. Probe labeling and hybridization
were performed by NimbleGen (Reykjavik, Iceland).
Quantitative PCR analysis
Selected promoters were verified by SYBR Green quantita-
tive PCR analysis. Primers were designed using Primer
Express v2.0 (Applied Biosystems, Foster City, CA, USA).
Each PCR reaction was performed in duplicate in a 25 ml
reaction with 5 ng of LM-PCR amplified input or ChIP
DNA and 1× Power SYBR Green master mix (Applied Bio-
systems). Fluorescence values were determined by ABI
Prism 7900 HT sequence detection system. Fold enrich-
ment was calculated in terms of occupancy units as
described in Yang et al. [8]. Fold enrichment (OU) = 1.9-
(delta CT
expt
-delta CT
Tk1) where delta CT = CTIP-CTInput. Specif-
icity of the PCR reaction was confirmed by the presence of
a single peak in dissociation curve analysis and a single
product on agarose gel. Primer sequences are listed in
Additional file 10.
Data analysis for NimbleGen promoter arrays
A MAP algorithm was developed based on the MAT algo-
rithm [17] to identify p53 and p73 ChIP-enriched sites.
Details are described in Additional file 2. ChIP-chip data-
sets have been deposited in the Gene Expression Omnibus
(GEO) database under the accession number GSE12224.
siRNA transfection
siRNA duplexes against p53, p73, and lacZ were obtained
from Dharmacon (Lafayette, CO, USA) as described in
Chau et al. [39]. HCT116-3(6) cells were transfected in
suspension with RNA duplexes using Oligofectamine
(Invitrogen).
shRNA and lentiviral infection
We used p73 MISSION shRNA (NM_005427) (Sigma) to
establish stable p73 knockdown cell lines from HCT116-
3(6). pRS-lacZ and pRS-p53, kindly provided by Brum-
melkamp et al. [41], were used to establish stable p53
knockdown cell lines from HCT116-3(6) cells. HCT116-
3(6) cells were transduced with viral supernatants con-
taining p73 shRNA or p53 shRNA collected from 293
amphotropic packing cell lines 48 hours following trans-
fection using a standard virus transduction protocol.
Infected cells were selected for puromycin resistance and
were re-seeded at low density to obtain single colonies.
Positive clones were confirmed by Western blotting anal-
ysis.
Gene expression analysis
Total RNA from HCT116-3(6) cells transiently transfected
with lacZ or p53/p73 siRNA oligos with/without treat-
ment of HU was isolated using RNeasy Mini Kit (Qiagen),
according to the manufacturer's instructions. Total RNA
was converted to cRNA, labeled with Cy5 or Cy3 dUTP
using Agilent low input linear RNA amplification, and the
resulting cRNA was hybridized to the Phalanx Human
One array. After hybridization, the slides were scanned
with Axon 4000 B, and the raw data were generated by
Genepix 6.0. Four biological repeats were performed for
each condition (-HU or +HU), with two technical repeats
(dye swap) per biological sample. The data were normal-
ized with quantile normalization of DNAMR [42] and fit-
ted with the linear model from the R package Limma [43].
Two comparisons were performed: Gene expression in
lacZ siRNA-transfected cells versus p53 and p73 siRNA-
transfected cells in the -HU or +HU condition. P value was
calculated using t-statistics. To integrate ChIP-chip data
with gene expression profiling, we first selected genes
common to the two array platforms. We then selected pro-
moters from the four experiments using FDRMAP < 0.05.
Promoters whose expression was affected by p53/p73
knockdown are shown (P  < 0.1). Raw data have been
deposited in the GEO database under the accession
number GSE12242.
RNA extraction and real-time RT-PCR analysis
Total RNA was extracted by using RNeasy Mini Kit (Qia-
gen), according to the manufacturer's instructions. TotalBMC Biology 2009, 7:35 http://www.biomedcentral.com/1741-7007/7/35
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RNA (500 ng to 1 mg) was reverse transcribed by using the
High-Capacity cDNA Archive Kit (Applied Biosystems).
The resulting cDNA samples were subjected to RT-PCR
analysis using the following gene-specific primers.
p21cip1: GCAGACCAGCATGACAGATTTCT (fwd), GCG-
GATTAGGGCTTCCTCTT (rev). MLH3: CCTGCTTGAG-
GGCTGCAT (fwd), CTCAAATTGGTCTGGCCTTAAAA
(rev). ETF1: CCAAGGAGCATACCCATGGT (fwd), AAGT-
TCTGGAAATGTTCCAATTGTAA(rev), ACTB: CGAGAA-
GATGACCCAGATCATGTT (fwd), CCTCGTAGATGGGC
ACAGTGT (rev).
GO term analysis
Functional classifications of target genes were performed
using the web-based program Database for Annotation,
Visualization, and Integrated Discovery (DAVID) [44].
Each identified category is provided by a P value of the
likelihood of finding the identified category by random
chance. Categories represented >5% with P < 0.01 were
selected.
Motif search
Using the cut-off of FDRMAP < 0.005, we extracted the 2.5-
kb query sequence (1.5-kb probe region plus 500 bp sur-
rounding either side of the 1.5-kb probe region in each
promoter) from the human chromosome build 35 (hg17)
assembly. We used p53scan [13,45] to search for p53
motifs in p53- and p73-bound promoters. We also
searched p53- and p73-bound promoters against the JAS-
PAR database [46] using the motif search program Cis-
eLement OVERrepresentation [47] for other over-repre-
sented motifs corresponding to 123 curated transcription
factor-binding motifs using P value cutoff < 0.001.
Correlation analysis
Correlation between ChIP-chip experiments is deter-
mined by calculating the Pearson correlation coefficient
(r) derived from linear regression analysis. P values were
calculated to test the significance of the correlation. The
test statistic is based on Pearson's product moment corre-
lation coefficient cor(x, y) and a t distribution with
length(x)-2 degrees of freedom, assuming the samples fol-
low independent normal distributions.
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